High dose ace inhibitor can it improve renoprotection

Navis G et al. High-dose ACE inhibition: Can it improve renoprotection? Am J Kidney Dis Sep Angiotensin-converting-enzyme ACE inhibitors are used both to lower blood pressure and to reduce proteinuria in certain patients with renal disease. Comment In this study, maximal antihypertensive and antiproteinuric doses of an ACE inhibitor were similar.

Citation s : Haas M et al. October 26, Critical Care Medicine. New York. Seeking Academic Gastroenterologists. Ann Arbor, Michigan.

Family Medicine. Body weight. Left kidney. Blood Urea. Open in new tab. Table 2 Albuminuria and Blood pressure. Albuminuria 2 months. Albuminuria 3 months. MABP 3 months. Open in new tab Download slide. Table 3 Morphologic indices of renal damage. Volume of mesangial. Table 4 Glomeruli: number, size and capillaries. Mean glomerular.

Table 5 Cellular analysis of the glomerulus. Endothelial cells. Mesangial cells. Table 6 Immunohistochemical results. Collagen IV. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Google Scholar Crossref. Search ADS. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Google Scholar PubMed.

The renin—angiotensin system and progression of renal disease: from hemodynamics to cell biology. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.

Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. The intrarenal renin—angiotensin system: a paracrine system for the local control of renal function separate from the systemic axis. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease.

RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen.

How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. Effect of renin—angiotensin—aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.

Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Protective effect of combining ACE inhibition and aldosterone receptor blockade on renal structural damage in experimental nephrosis. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis.

Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. Chronic renal failure after nephrotoxic nephritis in rats: contributions to progression.

Effect of 1,25 OH 2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.

Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.

Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.

Determinants of blood pressure response to quinapril in black and white hypertensive patients: the quinapril Titration Interval Management Evaluation trial. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.

All rights reserved. For Permissions, please e-mail: journals. Issue Section:. Download all slides. Supplementary data. Supplementary Data - zip file. Comments 0. Add comment Close comment form modal. I agree to the terms and conditions. You must accept the terms and conditions. Add comment Cancel. Submit a comment. Comment title. You have entered an invalid code. Submit Cancel. Thank you for submitting a comment on this article.

Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email. View Metrics. Email alerts Article activity alert. Advance article alerts. J Am Soc Nephrol 15 : — American Diabetes Association Standards of medical care for patients with diabetes mellitus.

Diabetes Care 25 : — American Diabetes Association Standards of medical care in diabetes Diabetes Care 29 Suppl 1 : S4—S Pohl MA et al. J Am Soc Nephrol 16 : — Gall MA et al. BMJ : — Ibrahim HA et al. Leoncini G et al.

J Hum Hypertens 16 : — Wachtell K et al. Ann Intern Med : — Parving HH et al. Viberti G and Wheeldon NM Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation : — Ibsen H et al. Hypertension 45 : — Drugs 66 : 51— Makino H et al.

J Int Med Res 33 : — Barnett AH et al. Schmieder RE et al. J Hypertens 23 Suppl : S Google Scholar. Ravid M et al. A randomized, controlled trial.

Semin Nephrol 24 : — Valmadrid CT et al. Arch Intern Med : — Acta Diabetol 42 Suppl 1 : S42—S J Hypertens 21 Suppl : S37—S Aranda P et al. Am J Kidney Dis 46 : — Wolf G and Ritz E Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.

Kidney Int 67 : — MacKinnon M et al. Am J Kidney Dis 48 : 8— Sengul AM et al.